Replicor's Compassionate Access Program Shows Promising Results for HBV/HDV Patients
Replicor Inc., a biopharmaceutical company, has published data from its first global compassionate access program in the Journal of Hepatology. The program, initiated with Dr. Marc Bourlière in France, involved the use of REP 2139-Mg in patients with chronic HBV/HDV infection who had previously failed treatments with bulevirtide or lonafarnib and had cirrhosis or decompensated cirrhosis. The program treated 33 patients across 16 sites in 8 countries. Key findings include the excellent safety profile of REP 2139-Mg, rapid reversal of decompensation symptoms, high rates of HDV cure, and HBV functional cure. The treatment also led to the elimination of HBV and HDV from the liver after as little as 10 weeks of therapy. Dr. Andrew Vaillant, CSO of Replicor, highlighted the unique bifunctional nature of REP 2139, which targets HDV replication and subviral particle assembly, and noted the promising safety and efficacy results even in patients with decompensated cirrhosis. 
